Fintel reports that on January 12, 2026, Goldman Sachs upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from Neutral to Buy.
Analyst Price Forecast Suggests 53.51% Upside
As of December 21, 2025, the average one-year price target for Crinetics Pharmaceuticals is $81.75/share. The forecasts range from a low of $45.45 to a high of $113.40. The average price target represents an increase of 53.51% from its latest reported closing price of $53.25 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Crinetics Pharmaceuticals is 180MM, an increase of 11,614.66%. The projected annual non-GAAP EPS is -3.08.
What is the Fund Sentiment?
There are 520 funds or institutions reporting positions in Crinetics Pharmaceuticals. This is an decrease of 21 owner(s) or 3.88% in the last quarter. Average portfolio weight of all funds dedicated to CRNX is 0.25%, an increase of 11.47%. Total shares owned by institutions increased in the last three months by 1.97% to 122,937K shares. 
The put/call ratio of CRNX is 0.88, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 8,382K shares representing 8.18% ownership of the company. In its prior filing, the firm reported owning 5,807K shares , representing an increase of 30.72%. The firm decreased its portfolio allocation in CRNX by 71.47% over the last quarter.
Driehaus Capital Management holds 6,482K shares representing 6.32% ownership of the company. In its prior filing, the firm reported owning 6,400K shares , representing an increase of 1.26%. The firm increased its portfolio allocation in CRNX by 31.30% over the last quarter.
Farallon Capital Management holds 5,770K shares representing 5.63% ownership of the company. In its prior filing, the firm reported owning 4,646K shares , representing an increase of 19.48%. The firm increased its portfolio allocation in CRNX by 70.65% over the last quarter.
Price T Rowe Associates holds 5,306K shares representing 5.18% ownership of the company. In its prior filing, the firm reported owning 5,591K shares , representing a decrease of 5.36%. The firm increased its portfolio allocation in CRNX by 29.82% over the last quarter.
EcoR1 Capital holds 4,288K shares representing 4.18% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
